학술 및 논문 자료 14

1. Author(year): Breidthardtet al.(2013)

2. Study: Basel

3. Population: ADHF in ED

4. Study description: Serial ST2 levels; evaluated early responders(≥25% drop in ST2 at 48h) vs nonresponders, and interactions with treatments

5. N: 207

6. Average age(year): 80

7. Average LVEF(%): 40

8. Primary outcome: Death

9. Follow-up duration: 1 year

10. Summary of findings: Poorer prognosis in ST2 nonreponders; survival benefits from β-blockers only seen in nonresponders.

11. Link:


1. Author(year): Shah et al. (2011)

2. Study: Multicenter

3. Population: Dyspnea in ED

4. Study description:  ST2 and NT-proBNP in ED patients; 5-center cohort study; n=200 with preserved LVEF 

5. N: 387

6. Average age(year): 58

7. Average LVEF(%): >50 in 200

8. Primary outcome: Death

9. Follow-up duration: 1 year

10. Summary of findings: ST2 associated with mortality, was the only independent predictor in the subgroup with normal LVEF.

11. Link:

1. Author(year): Socrates et al. 2010)

2. Study: Multicenter, international

3. Population: Dyspnea in ED

4. Study description: ST2, BNP and NT-proBNP in ED

5. N: 1091

6. Average age(year): 69

7. Average LVEF(%): 55

8. Primary outcome: Death

9. Follow-up duration: 30 days, 1 year

10. Summary of findings: ST2 levels were predictive at both time point; addictive to NPs.

11. Link: https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1365-2796.2010.02263.x

1. Author(year): Dieplinger et al. (2010)

2. Study: Linz, Austria

3. Population: Dyspnea in ED

4. Study description: 10 markers

5. N: 251

6. Average age(year): 73

7. Average LVEF(%): 50

8. Primary outcome: Death

9. Follow-up duration: 1 year

10. Summary of findings: Only ST2, MR-proANP and CgA independently predicted outcome.

11. Link: https://www.sciencedirect.com/science/article/abs/pii/S0009912010000615


1. Author(year): Rehman et al.(2008)

2. Study: Linz+PRIDE

3. Population: Acute HF; ED patients

4. Study description: ST2 and NT-proBNP; Evaluated echocardiographic correlates

5. N: 346

6. Average age(year): 73

7. Average LVEF(%): 45

8. Primary outcome: Death

9. Follow-up duration: 1 year

10. Summary of findings: ST2 levels equally predictive in HF with preserved or reduced EF.

11. Link: https://www.jacc.org/doi/pdf/10.1016/j.jacc.2008.07.042


1. Author(year): Mueller et al.(2008)

2. Study: Linz

3. Population: ADHF in ED

4. Study description: ST2 measured in ED

5. N: 137

6. Average age(year): 76

7. Average LVEF(%): 39

8. Primary outcome: Death

9. Follow-up duration: 1 year

10. Summary of findings: ST2 levels associated with mortality.

11. Link: https://bit.ly/3GiPMEe

1. Author(year): Januzzi et al.(2007)

2. Study: PRIDE

3. Population: Dyspnea in ED

4. Study description: ST2 and NT-proBNP measured in ED

5. N: 593

6. Average age(year): 63

7. Average LVEF(%): N/A

8. Primary outcome:  Death

9. Follow-up duration: 1 year

10. Summary of findings: ST2 is associated with mortality, complementary to NT-proBNP

11. Link: https://www.jacc.org/doi/pdf/10.1016/j.jacc.2007.05.014

1. Author(year): Van Vark et al. (2017)

2. Study: TRIUMPH

3. Population: Hospitalized for acute HF

4. Study description: Prognostic value of baseline and repeated ST2 measurements in patients with acute HF

5. N: 496

6. Average age(year): 74

7. Average LVEF(%): 30

8. Primary outcome:  All-cause mortality and readmission for HF

9. Follow-up duration: 1 year

10. Summary of findings: The repeated measurements of ST2 are a strong and independent predictor of adverse outcome in patients following admission for acute HF. The repeated ST2 measurements identified patients at a substantially higher risk of adverse events than did baseline ST2 levels alone. In addition, repeated ST2 measurements offer incremental prognostic value to that conferred by other known risk factors and , importantly, repeated measurements of NT-proBNP.

11. Link: https://www.jacc.org/doi/pdf/10.1016/j.jacc.2017.09.026

1. Author(year): Demissei et al. (2016)

2. Study: RELAX-AHF

3. Population:  

4. Study description:  Prognostic value of multi-time point-based multimarker panel of biomarkers in patients with acute heart failure

5. N: 1161

6. Average age(year): 72±11.2

7. Average LVEF(%): 45.2% ≥40%

8. Primary outcome: Cardiovascular mortality with 180 days

9. Follow-up duration: 180 days

10. Summary of findings:  

A combination of biomarkers reflecting diverse pathophysiological pathways provides significant prognostic improvement on top of readily available clinical and laboratory parameters unmatched by any single biomarker. Multimarker models are highly accurate and objective risk stratification tools that can play a crucial role in the development of need-based, personalized treatment strategies in AHF.

11. Link: https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.749

1. Author(year): Mebazza et al. (2015)

2. Study: 

3. Population: Hospitalized for ADHF 

4. Study description:  ST2 and multimarker testing in ADHF

5. N: 

6. Average age(year): 

7. Average LVEF(%): 

8. Primary outcome: 

9. Follow-up duration: 

10. Summary of findings:  

Kaplan-Meier confirmed a twofold increased risk of death in patients with ADHF with elevated plasma levels of ST2 or CRP and fourfold increased risk if both CRP and ST2 were elevated.

11. Link: https://core.ac.uk/download/pdf/74320174.pdf